BC Extra | Jan 13, 2020
Company News

MorphoSys nets $900M up front in global deal with Incyte for anti-CD19 mAb

The first major deal under the watch of MorphoSys’ new CEO Jean-Paul Kress triples the German biotech’s cash position through a global partnership with Incyte to develop and commercialize blood cancer therapy tafasitamab. While the...
BC Extra | Dec 12, 2019
Company News

Dec. 11 Company Quick Takes: Kite, Alkermes, argenx, Reblozyl, Denovo-Sunesis

Kite submits BLA for CD19 CAR T in mantle cell  Kite Pharma Inc. submitted Wednesday a BLA to FDA for KTE-X19 to treat mantle cell lymphoma after reporting Phase II data at the American Society...
BC Week In Review | Dec 7, 2018
Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
BC Extra | Dec 4, 2018
Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
BC Week In Review | Nov 2, 2018
Clinical News

argenx's CD70 mAb leads to 92% response rate in AML

In an abstract released ahead of next month’s American Society of Hematology meeting, argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said cusatuzumab (ARGX-110) plus Vidaza azacitidine led to an overall response rate (ORR) of 92% in the Phase...
BC Extra | Nov 1, 2018
Clinical News

argenx's CD70 mAb leads to 92% response rate in AML

In an abstract released ahead of next month’s American Society of Hematology meeting, argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said cusatuzumab (ARGX-110) plus Vidaza azacitidine led to an overall response rate (ORR) of 92% in the Phase...
BioCentury | Dec 16, 2017
Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
BC Week In Review | Dec 15, 2017
Financial News

argenx raises $231M in follow-on

Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) raised $231 million through the sale of 4.4 million ADSs at $52 in a bumped-up follow-on underwritten by Cowen, Piper Jaffray, JMP Securities and Wedbush PacGrow. The price is...
BC Week In Review | Dec 15, 2017
Clinical News

argenx reports Phase I/II cancer data of CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) reported data from two Phase I/II trials of ARGX-110 at the American Society of Hematology (ASH) meeting in Atlanta. Preliminary data from six evaluable patients with newly diagnosed acute myelogenous leukemia...
BC Extra | Dec 14, 2017
Financial News

argenx, Proteostasis, Dicerna raise follow-ons

Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX), respiratory company Proteostasis Therapeutics Inc. (NASDAQ:PTI) and RNA therapeutics play Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) raised a combined $311 million in follow-on offerings. argenx raised $231 million through the sale...
Items per page:
1 - 10 of 31